mitoquinone has been researched along with Endotoxemia* in 2 studies
2 other study(ies) available for mitoquinone and Endotoxemia
Article | Year |
---|---|
Mitochondrial anti-oxidant protects IEX-1 deficient mice from organ damage during endotoxemia.
Sepsis, a leading cause of mortality in intensive care units worldwide, is often a result of overactive and systemic inflammation following serious infections. We found that mice lacking immediate early responsive gene X-1 (IEX-1) were prone to lipopolysaccharide (LPS) -induced endotoxemia. A nonlethal dose of LPS provoked numerous aberrations in IEX-1 knockout (KO) mice including pancytopenia, increased serum aspartate aminotransferase (AST), and lung neutrophilia, concurrent with liver and kidney damage, followed by death. Given these results, in conjunction with a proven role for IEX-1 in the regulation of reactive oxygen species (ROS) homeostasis during stress, we pre-treated IEX-1 KO mice with Mitoquinone (MitoQ), a mitochondrion-based antioxidant prior to LPS injection. The treatment significantly reduced ROS formation in circulatory cells and protected against pancytopenia and multiple organ failure, drastically increasing the survival rate of IEX-1 KO mice challenged by this low dose of LPS. This study confirms significant contribution of mitochondrial ROS to the etiology of sepsis. Topics: Animals; Antioxidants; Blood Cell Count; Data Interpretation, Statistical; Endotoxemia; Endotoxins; Immediate-Early Proteins; Kaplan-Meier Estimate; Kidney; Liver; Lung; Membrane Potential, Mitochondrial; Mice, Knockout; Mitochondria; Organophosphorus Compounds; Reactive Oxygen Species; Ubiquinone | 2014 |
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
Sepsis elicits severe alterations in cardiac function, impairing cardiac mitochondrial and pressure-generating capacity. Currently, there are no therapies to prevent sepsis-induced cardiac dysfunction. We tested the hypothesis that administration of a mitochondrially targeted antioxidant, 10-(6'-ubiquinonyl)-decyltriphenylphosphonium (MitoQ), would prevent endotoxin-induced reductions in cardiac mitochondrial and contractile function. Studies were performed on adult rodents (n = 52) given either saline, endotoxin (8 mg x kg(-1) x day(-1)), saline + MitoQ (500 microM), or both endotoxin and MitoQ. At 48 h animals were killed and hearts were removed for determination of either cardiac mitochondrial function (using polarography) or cardiac pressure generation (using the Langendorf technique). We found that endotoxin induced reductions in mitochondrial state 3 respiration rates, the respiratory control ratio, and ATP generation. Moreover, MitoQ administration prevented each of these endotoxin-induced abnormalities, P < 0.001. We also found that endotoxin produced reductions in cardiac pressure-generating capacity, reducing the systolic pressure-diastolic relationship. MitoQ also prevented endotoxin-induced reductions in cardiac pressure generation, P < 0.01. One potential link between mitochondrial and contractile dysfunction is caspase activation; we found that endotoxin increased cardiac levels of active caspases 9 and 3 (P < 0.001), while MitoQ prevented this increase (P < 0.01). These data demonstrate that MitoQ is a potent inhibitor of endotoxin-induced mitochondrial and cardiac abnormalities. We speculate that this agent may prove a novel therapy for sepsis-induced cardiac dysfunction. Topics: Adenosine Triphosphate; Animals; Antioxidants; Caspase 3; Caspase 9; Cell Respiration; Disease Models, Animal; Drug Administration Schedule; Endotoxemia; Enzyme Activation; Heart Diseases; Mice; Mitochondria, Heart; Myocardial Contraction; Myocardium; Organophosphorus Compounds; Protein Carbonylation; Rats; Tumor Necrosis Factor-alpha; Ubiquinone; Ventricular Function, Left; Ventricular Pressure | 2009 |